Glycolytic activity was previously correlated with active immune signatures in cancer, as highly glycolytic tumors present an immune-stimulatory tumor microenvironment, and even correlating with immune checkpoints such as PD-L1 expression in tumors [8]. This evidence concerns the gene CD274 and cancer.